Background: Patients with metastatic Merkel cell carcinoma are treated similarly to small cell lung cancer (SCLC). Poly ADP-ribose polymerase-1 (PARP1) is overexpressed in SCLC and response to PARP inhibitors have been reported in patients with SCLC. Our study explores PARP as a therapeutic target in Merkel cell carcinoma.
the geriatric and immunocompromised populations. It has an incidence of 1500 new cases per year in the United States and it is mostly seen in light-skinned men. 1 The most common primary sites for Merkel cell carcinoma are the head and neck or extremities. 1 Although the tumor's exact cell of origin and pathogenesis are unknown, Merkel cell polyomavirus (MCPyV) and UV radiation are associated with the development of Merkel cell carcinoma. 2 The MCPyV, a double-stranded DNA virus, is monoclonally integrated in 40%-80% of Merkel cell carcinomas. 2 The
MCPyV can be detected by polymerase chain reaction targeting the LTA coding gene or by immunohistochemistry (IHC) using a monoclonal antibody against the antigenic epitope.
Although the majority of patients with Merkel cell carcinoma present with local disease amenable to surgery and/or radiotherapy, tumor recurrence occurs in at least 35% of the cases. 3 Patients with stage IV disease have a dismal prognosis with a 5-year survival ranging from 0%-18%. 4 Given its histological similarities with small cell lung cancer (SCLC), the combination of platinum and etoposide or single-agent topotecan are frequently used to treat patients with incurable disease. Platinum and etoposide in the first-line setting renders responses in approximately 60% of the patients, usually short-lived, which is similar to that observed in patients with SCLC. [5] [6] [7] Recently, sequencing efforts in Merkel cell carcinoma have shed light into the genomic landscape of this disease. [8] [9] [10] [11] [12] Interestingly, although the mutational profile of MCPyV-negative tumors mirrors SCLC, with the vast majority of cases harboring mutations in TP53 and RB1 and scarce actionable mutations in oncogenes, MCPyV-positive tumors have a lower mutational burden, with virtually no mutations in TP53 or RB1. Few mutations were identified in targetable oncogenes overall, however, abnormalities in genes involved in DNA repair pathways have been described in approximately 30% of the cases. 8, 12 Byers et al 13 have reported a high expression of DNA repair proteins in SCLC at the mRNA and protein levels, particularly poly ADP-ribose polymerase-1 (PARP1). High levels of PARP1 and other proteins involved in DNA-damage repair, such as FANCD2 and pCHK2, are strongly associated with sensitivity of SCLC cell lines to PARP inhibitors. 14 Furthermore, responses to PARP inhibitors in patients with metastatic SCLC have been reported, which led to a series of ongoing clinical studies testing PARP inhibitors as a single agent or in combination with chemotherapy in SCLC. 13, [15] [16] [17] Based on the similar histology, response to platinum and mutational background between Merkel cell carcinomas, particularly MCPyV-negative and SCLC, the identification of mutations in genes involved in DNA-damage repair in Merkel cell carcinoma, and the promising antitumor activity of PARP inhibitors in SCLC, the purpose of this study was to explore PARP1 as a potential therapeutic target in Merkel cell carcinoma.
| MA TERI A LS AND M ETH ODS

| Sample selection
The patient population consisted of 19 unequivocal Merkel cell carcinoma cases as determined by an experienced pathologist (D.B.) that were seen at MD Anderson Cancer Center in 2015 and had tissue available for IHC studies. Fourteen patients had sufficient samples for target exome sequencing. Clinical data were retrospectively obtained from electronic medical records according to the institutional review board approved protocol RCR04-0030. Data acquisition was locked on December 1, 2015 . At the analysis of data, 18 patients were alive. Vital status was unknown for 1 patient.
| Immunohistochemistry
The IHC analysis for PARP1 (clone A6.4.12; LSBio) was performed in 4 micron paraffin-embedded tissue sections using BOND MAX IHC staining protocol by Vision Biosystems platform. Polyomavirus status was evaluated by staining with anti-MCPyV antibody (clone CM2B4; Santa Cruz) in the tissue specimens. Intensity of the staining was graded as 0 (no staining), 11 (weak), 21 (moderate), or 31 (strong). The percentage of cells (0%-100%) staining for each intensity was determined. The H-score was calculated by multiplying the staining intensity (0-31) by the percent of cells of each intensity (0%-100%), and then by adding these together for a final score of 0 to 300. Only tumor tissue with strong nuclear staining in >10% of the neoplastic cells (H-score >30) was considered positive. Tumor tissue with an H-score >200 was considered strongly positive.
| Genomic analysis
Targeted exome sequencing of 263 genes (T200 institutional panel) was done in DNA extracted from paraffin-embedded section of 14 patients using next-generation sequencing 18 and is available in the Supporting Information Material online. Paired peripheral blood mononuclear cells were not available for analysis of germline mutations. In order to select for mutation in genes of interest likely to impact protein function (oncogenic), we used the following approach: (a) searched for the mutation in The Cancer Genome Atlas ). If no information was found in the The Cancer Genome Atlas or provided by the mutation effect predictor algorithms, we included frame shift mutations, inframe codon loss or gain, and stop-gained mutations likely to impair protein function.
| Cell lines
Human Merkel cell carcinoma cell lines MKL-1, MS-1, MCC-13, and MCC-26 were obtained from Sigma-Aldrich (St Louis, MO). All cells were grown in suggested medium supplemented with fetal bovine serum and penicillin/streptomycin. Cells were passaged for fewer than 6 months after receipt.
| Western blot
Western blots of cell lysates were probed for PARP1 (cs9542; Cell Signaling Technology, Danvers, MA), and actin (sc47778; Santa Cruz Biotechnology, Dallas, TX).
| Proliferation assays
Cells were seeded in 96-well plates at 2000 cells per well in triplicate for each cell line. After 24 hours, the cells in each well were treated for 24 hours with the PARP inhibitor olaparib (Selleck Chemicals, Houston, TX), cisplatin, or vehicle control. Four days later, proliferation was assayed by Cell Titer Glo (Promega, Fitchburg, WI). Median inhibitory concentration values were estimated using the Drexplorer software (MD Anderson Cancer Center).
| Statistical analysis
Descriptive statistics were used to report continuous and categorical variables. Fisher's exact test was applied to describe the association among PARP1 expression, MCPyV status, mutations in genes of interest, and patient's clinical characteristics. All P values were 2-sided. The P values < .05 were considered statistically significant.
| R ES ULT S
| Population characteristics
Baseline characteristics of the 19 patients with Merkel cell carcinoma are outlined in Table 1 . The median age at diagnosis was 72 years old, and 68% (13/19) of the patients had a primary tumor in the head and neck region. Three patients were significantly immunosuppressed due to leukemia (chronic lymphocytic or myelomonocytic) or therapy for rheumatoid arthritis. A medical history of solid tumor was positive in 14 patients, the most common being other skin cancers (basal cell or squamous cell carcinoma) diagnosed in 8 patients, prostate cancer in 4 patients, and breast cancer in 2 patients. Overall, 15 patients (79%) had a history of liquid or solid malignancy. with MCPyV. Interestingly, PARP1 expression was detected in the vast majority of cases (84%), as demonstrated in Figure 1 . Of the 16 samples that stained positive for PARP, 13 had an H-score of 300. The PARP1 expression was detected in both MCPyV-positive (9/9) and MCPyV-negative (7/10) tumors, with no statistical correlation between PARP1 expression and MCPyV status or primary site of disease. The results of the IHC studies are outlined in Table 2 .
| Prevalence of immunohistochemical markers of interest
| Mutations in genes related with DNA damage repair
Of the 19 patients, 14 had adequate tissue for targeted exome sequencing. Of 263 genes analyzed (Supporting Information  Table S1 ), 12 (ATM, ATR, ATRX, BRCA1, BRCA2, PALB2, RAD51, RAD51C, CHEK1, CHEK2, FANCA, and FANCD2) are related to DNA-damage repair and 4 genes (MLH1, MSH2, MSH6, and PMS2) are involved in mismatch repair (MMR). 24, 25 We also included mutations in the tumor suppressor gene ARID1A, a component of the SWI/SMF chromatin-remodeling complex, as loss-of-function mutation in this gene has been associated with sensitivity to PARP inhibitors preclinically. 26 Oncogenic mutations in the tumor suppressor genes TP53 and RB1 were annotated. They cooccurred in the majority of samples. As demonstrated in Figure 2 , 9 of 14 patients (64%) had mutations in at least one gene involved in DNA-damage repair and/or MMR. Predicted loss-of-function mutations in ARID1A were identified in 5 samples. The annotations of the mutations are specified in Supporting Information Table S2 . 
| Correlations between poly ADP-ribose polymerase staining, gene mutations, and clinicohistological characteristics
Using Fisher's exact test, no statistically significant correlation was found between PARP1 IHC staining (positive vs negative) and MCPyV status (positive vs negative), tumor primary site (head and neck vs extremities), or mutations in any of the 17 genes of interest described above (present vs absent). Interestingly, mutations in genes involved in DNAdamage repair, MMR, or ARID1A, were found exclusively in patients with a head and neck primary (see Figure 2) . The TP53 or RB1 loss-of-function mutations were also restricted to tumors arising in the head and neck (P 5 .03). Mutations in genes of interest were likely to co-occur with TP53 or RB1 mutations (P 5 .03; Supporting Information Figure S1 ).
The ARID1A mutations were found exclusively in the MCPyV-negative samples (P 5 .003). Mutations in TP53 or RB1 also correlated with MCPyV-negative status (P 5 .03; Supporting Information Figure S2 ).
| Poly ADP-ribose polymerase inhibitor activity in Merkel cell carcinoma cell lines
Having observed high PARP1 expression in patient samples, we assayed PARP1 expression in a panel of Merkel cell carcinoma cell lines that included 2 MCPyV-positive (MKL-1 and MS-1) and 2 that were MCPyV-negative (MCC-13 and MCC-26). Three SCLC cell lines with relatively low, moderate, and high PARP1 expression were included for comparison (see Figure 3) . In all 4 cell lines, Western blot analysis revealed PARP expression in Merkel cell carcinoma lines that was on a par with SCLC cell lines with moderate (H378) to high (DMS153) PARP1 expression ( Figure 3A) . To assay the potential sensitivity of Merkel cell carcinoma to PARP inhibition, we tested the efficacy of the Food and Drug Administration approved PARP inhibitor, olaparib, in our cell line panel. Of the 4 cell lines tested, the one with the highest level of PARP1 expression (MKL-1) was sensitive to olaparib ( Figure 3B ). Similar to observations in SCLC 14 sensitivity to olaparib and cisplatin were correlated (R 5 0.921 by Pearson correlation).
| DI S CU S S IO N
New, more effective and well-tolerated therapy is greatly needed for patients with recurrent Merkel cell carcinoma, many of whom are elderly and chronically immunosuppressed. Recent trials have demonstrated benefit from immune checkpoint inhibition with pembrolizumab and avelumab, anti-programmed death-1 and programmed death ligand-1, respectively, in a subset of patients with Merkel cell carcinoma. 27, 28 Although these data are promising, it is notable that some patients with Merkel cell carcinoma require active immunosuppression for autoimmune disorders or organ transplant status, and, thus, are not candidates for immune checkpoint inhibition. In order to explore other novel therapeutic options for incurable Merkel cell carcinoma, we investigated the expression of PARP1 by IHC in patients with Merkel cell carcinoma and found it to be strongly positive in 74% of patients. Our findings are similar to those in SCLC, in which PARP1 overexpression is identified in the majority of cases. 13 The mechanism of PARP1 overexpression in SCLC is thought to be secondary to RB1 loss, which leads to increased expression of the transcription factor E2F1 and activation of its targets, including several components of DNA repair pathways. 13 In our series, mutations in the tumor suppressors genes RB1 and/or TP53 were identified in 6 of 14 patients (43%), and were more frequent in the MCPyV-negative tumors, consistent with the available literature. 9, 11 Alternative mechanisms other than mutations leading to inactivation of TP53 or RB1, such as complexes gene rearrangements were not tested in our samples. Therefore, because PARP1 is a key facilitator of singlestranded DNA breaks repair, the level of PARP1 protein generally increases in response to DNA damage. 29 In order to investigate the frequency of mutations in genes involved in DNA-damage repair, we performed exome-sequencing of 263 genes, including 16 known to be involved in DNAdamage repair pathways [30] [31] [32] in 14 available Merkel cell carcinoma samples and found that 9 patients (64%) had mutation in at least one of these genes. No correlation was seen between PARP1 expression and the presence of mutations in genes involved in DNA-damage repair.
Other groups have also described mutations in DNAdamage repair genes in Merkel cell carcinoma, however, at a lower frequency rate. 10, 12 In our series, 53% of the patients were MCPyV-negative, likely due to our center's geographic location subject to intense sun exposure. The MCPyVnegative tumors have a DNA-damage UV signature very distinct from MCPyV-positive tumors, 9 which may have accounted for the higher incidence of mutations in DNAdamage repair genes identified in our series. Indeed, mutations in genes associated with DNA-damage repair were exclusively identified in primary tumors of the head and neck, an area heavily exposed to the sun. Interestingly, we identified frequent mutations in ARID1A (36%). The ARID1A, a subunit of the SWI/SNF chromatin-remodeling complex, is involved in the regulation of the DNA damaging checkpoint via its interaction with ATR. Cell lines and xenograft models deficient in ARID1A are sensitive to PARP inhibitors, suggesting that specific loss-of-functions mutations in this gene might be a surrogate for benefit of this class of drugs. 26 Many PARP inhibitors are currently in late phase clinical development. Olaparib was the first PARP inhibitor to be Food and Drug Administration approved in refractory BRCA1/2 mutant metastatic ovarian cancer. 33 This drug was also granted breakthrough therapy designation in BRCA1/2 or ATM mutated castration-resistant prostate cancer. 34 Rucaparib and Niraparib, another 2 oral PARP inhibitors, are also approved for refractory BRCA1/2 mutant (germline or somatic) ovarian cancer in the chemotherapy refractory and in the maintenance setting, respectively. Beyond BRCA1/2 mutations, various strategies are being explored to select patients who are likely to benefit from PARP inhibitors, such as molecular characterization of aberrations in DNA repair genes, 34 expression, and epithelial-to-mesenchymal transition. 40 Broadly speaking, PARP1 expression is elevated in SCLC but only a subset respond to single-agent PARP inhibition. 16 On the basis of our experiments, Merkel cell carcinoma displays similar traits to SCLC, suggesting that better predictive markers and further testing, including PARP inhibitor combinations may enhance the effectiveness of single-agent PARP inhibitors. Given the recent approval of avelumab for patients with incurable Merkel cell carcinoma and the growing body of evidence demonstrating an increased therapeutic efficacy of PARP inhibitors combined with anti-programmed death ligand-1, this combination deserves clinical investigation in patients with this orphan disease. 41 Other combinations, such as PARP inhibitors and chemotherapy, 42 phosphotidylinositol-3-kinase inhibitors, 43 or CHK1 inhibitors 44 has shown promising activity in SCLC and may be clinically active in Merkel cell carcinoma. Taken together, in spite of the small sample size, the high prevalence of PARP1 overexpression in Merkel cell carcinoma, its sensitivity to platinum, the frequent mutations in genes involved in DNA-damage repair and ARID1A, particularly in the MCPyV-negative cases, and the sensitivity of Merkel cell carcinoma cell lines with high levels of PARP1 to olaparib suggest PARP inhibitors as single agent or in combination deserves clinical investigation in patients with Merkel cell carcinoma. Furthermore, based on the similarities between Merkel cell carcinoma and SCLC, basket trials for patient with rare high-grade neuroendocrine carcinomas irrespective of its organ of origin might be justified. 
FUNDING INFORMATION
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article. 
